A Phase 1 interventional study of Follitropin Delta in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 1 site in China. Open to female participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by Ferring Pharmaceuticals · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 12th largest by enrollment, is the only one that started in 2019, is the only one in phase 1, and was the 8th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 21 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2019.
This study's enrollment of 24 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 1, and was the 30th registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating hormone (rhFSH) under development by Ferring Pharmaceuticals. It is intended for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. In previous trials the exposure to and dose proportionality of FE 999049 in a clinically relevant dose range in Caucasian and Japanese healthy women have been shown to be very similar. This is a trial in healthy Chinese women investigating the pharmacokinetics, safety, and tolerability of a single subcutaneous dose of FE 999049.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
Drug: Follitropin Delta
Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
Drug: Follitropin Delta
Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
Drug: Follitropin Delta
Solution for Injection, subcutaneous administration
Also known as: REKOVELLE, FE 999049
Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)
Area under the concentration-time curve from dosing to infinity.
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)
AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Maximum Serum Concentration Observed (Cmax)
Maximum concentration observed in serum.
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Time of Maximum Observed Serum Concentration (Tmax)
Time of maximum observed concentration in serum.
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Apparent Total Systemic Clearance (CL/F)
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Terminal Elimination Half-life (t½)
Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)
Number of participants with clinically significant abnormal changes in ECG are presented.
Time frame: At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)
Number of Participants With Clinically Significant Abnormal Changes in Vital Signs
Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.
Time frame: At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)
Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters
Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.
Time frame: At screening, on Day -1 and Day 3, and at the follow-up visit (Day 11)
Number of Participants With Adverse Events (AEs) and Type of AEs
An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.
Time frame: From signed informed consent until the end-of-trial visit (Day 28)
Frequency of Injection Site Reactions
The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.
Time frame: Immediately, 30 minutes, and 24 hours after administration
Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies
Time frame: On Day 1 predose, Day 7, and Day 28
The trial was conducted at one site in China between June 2019 to December 2019.
| Milestone | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
Area under the concentration-time curve from dosing to infinity.
| h*ng/mL | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC) | 41.3 ± 44.3 | 62.9 ± 19.7 | 83.1 ± 36.6 |
AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.
| h*ng/mL | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt) | 36.4 ± 38.0 | 56.6 ± 18.7 | 74.6 ± 35.9 |
Maximum concentration observed in serum.
| ng/mL | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Maximum Serum Concentration Observed (Cmax) | 0.388 ± 26.5 | 0.677 ± 29.1 | 0.825 ± 34.6 |
Time of maximum observed concentration in serum.
| hour | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Time of Maximum Observed Serum Concentration (Tmax) | 24.0 (16.0 to 36.0) | 24.0 (16.0 to 48.0) | 24.0 (24.0 to 28.0) |
| Liter/hour | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Apparent Total Systemic Clearance (CL/F) | 0.301 ± 46.6 | 0.286 ± 19.7 | 0.289 ± 36.6 |
| Liter | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F) | 25.5 ± 19.5 | 20.8 ± 43.5 | 25.4 ± 31.5 |
| hour | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Terminal Elimination Half-life (t½) | 58.6 ± 47.5 | 50.5 ± 43.5 | 60.9 ± 13.6 |
Number of participants with clinically significant abnormal changes in ECG are presented.
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG) | 0 | 0 | 1 |
Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Changes in Vital Signs | 0 | 0 | 0 |
Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Clinical Chemistry | 2 | 1 | 1 |
| Haematology | 0 | 1 | 0 |
| Urinalysis | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Adverse events (AEs) | 5 | 4 | 3 |
| Serious AEs | 0 | 0 | 0 |
| Mild AEs | 5 | 3 | 3 |
| Moderate AEs | 0 | 1 | 0 |
| Severe AEs | 0 | 0 | 0 |
The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Frequency of Injection Site Reactions | 0 | 0 | 0 |
| Participants | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies | 0 | 0 | 0 |
Collected over From signed informed consent until the end-of-trial visit (Day 28). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Follitropin Delta (FE 999049) 12 μg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Follitropin Delta (FE 999049) 18 μg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Follitropin Delta (FE 999049) 24 μg | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg |
|---|---|---|---|
| Ventricular extrasystolesCardiac disorders | 0/8 | 0/8 | 1/8 |
| Procedural dizzinessInjury, poisoning and procedural complications | 1/8 | 0/8 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 1/8 | 0/8 |
| Aspartate aminotransferase increasedInvestigations | 1/8 | 1/8 | 0/8 |
| Blood urine presentInvestigations | 1/8 | 1/8 | 0/8 |
| Neutrophil count decreasedInvestigations | 0/8 | 1/8 | 0/8 |
| Red blood cells urine positiveInvestigations | 0/8 | 0/8 | 1/8 |
| Smear cervix abnormalInvestigations | 0/8 | 0/8 | 1/8 |
| White blood cell count decreasedInvestigations | 0/8 | 1/8 | 0/8 |
| Poor quality sleepNervous system disorders | 1/8 | 0/8 | 1/8 |
The full analysis set (FAS) comprised data from all dosed subjects. Subjects were analyzed according to the actual dose received.
| Age, Continuous(years) | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg | Total |
|---|---|---|---|---|
| Mean | 28.6 ± 6.0 | 29.5 ± 6.7 | 25.4 ± 4.6 | 27.8 ± 5.8 |
| Sex: Female, Male(Participants) | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 8 | 24 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 8 | 8 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 8 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | Follitropin Delta (FE 999049) 12 μg | Follitropin Delta (FE 999049) 18 μg | Follitropin Delta (FE 999049) 24 μg | Total |
|---|---|---|---|---|
| Mean | 22.2 ± 1.6 | 20.7 ± 1.9 | 22.0 ± 2.3 | 21.6 ± 2.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Nov 2019, 5 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta